Portal de Periódicos da CAPES

Pulmonary Hypertension

2013; American College of Physicians; Volume: 158; Issue: 9 Linguagem: Inglês

10.7326/0003-4819-158-9-201305070-01005

1539-3704

Jess Mandel, David Poch,

Pulmonary Hypertension Research and Treatments

In the Clinic7 May 2013Pulmonary HypertensionJess Mandel, MD, David Poch, MD, Deborah Cotton, MD, MPH, Darren B. Taichman, MD, PhD, and Sankey V. Williams, MDJess Mandel, MDSearch for more papers by this author, David Poch, MDSearch for more papers by this author, Deborah Cotton, MD, MPHSearch for more papers by this author, Darren B. Taichman, MD, PhDSearch for more papers by this author, and Sankey V. Williams, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-158-9-201305070-01005 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The pulmonary vascular bed is normally a low-resistance, high-capacitance circuit capable of accommodating the entire cardiac output at pressures approximately 15%–20% of those in the systemic circulation. In pulmonary hypertension (PH), elevated pulmonary arterial pressure places a burden on the normally thin-walled right ventricle as it works to maintain normal blood flow. Without effective therapy, right heart dysfunction leads to progressive symptoms and is often fatal. Pulmonary hypertension is frequently a result of common left-sided heart or lung diseases. Less frequently, it results from a disease process intrinsic to the pulmonary vasculature itself. Differentiating among the several causes of PH ...References1. Pengo V, Lensing AW, Prins MH, et al; Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350:2257-64. [PMID: 15163775] Google Scholar2. Galiè N, Hoeper MM, Humbert M, et al; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493-537. [PMID: 19713419] Google Scholar3. Brown LM, Chen H, Halpern S, et al. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest. 2011;140:19-26. [PMID: 21393391] Google Scholar4. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107:216-23. [PMID: 3605900] Google Scholar5. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102:865-70. [PMID: 10952954] Google Scholar6. Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest. 2006;129:1313-21. [PMID: 16685024] Google Scholar7. Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C, Ueland T. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol. 2006;98:525-9. [PMID: 16893710] Google Scholar8. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006;48:2546-52. [PMID: 17174196] Google Scholar9. McLaughlin VV, Archer SL, Badesch DB, et al; ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. Circulation. 2009;119:2250-94. [PMID: 19332472] Google Scholar10. Halpern SD, Taichman DB. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest. 2009;136:37-43. [PMID: 19255293] Google Scholar11. Krum H, Teerlink JR. Medical therapy for chronic heart failure. Lancet. 2011;378:713-21. [PMID: 21856485] Google Scholar12. Meyer T, Shih J, Aurigemma G. Heart failure with preserved ejection fraction (diastolic dysfunction). Ann Intern Med. 2013;158:ITC5-1-ITC5-15. [PMID: 23277912] Google Scholar13. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134:44-54. [PMID: 9266782] Google Scholar14. Packer M, McMurray J, Massie BM, et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail. 2005;11:12-20. [PMID: 15704058] Google Scholar15. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124:164-74. [PMID: 21709061] Google Scholar15a. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124;164-74. Google Scholar16. Fawzy ME, Hassan W, Stefadouros M, Moursi M, El Shaer F, Chaudhary MA. Prevalence and fate of severe pulmonary hypertension in 559 consecutive patients with severe rheumatic mitral stenosis undergoing mitral balloon valvotomy. J Heart Valve Dis. 2004;13:942-7; discussion 947-8. [PMID: 15597587] Google Scholar17. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1985;131:493-8. [PMID: 3922267] Google Scholar18. Huppmann P, Sczepanski B, Boensch M, et al. Effects of in-patient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J. 2012. [PMID: 23100507] Google Scholar19. Archer SL, Mike D, Crow J, Long W, Weir EK. A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD. Chest. 1996;109:750-5. [PMID: 8617086] Google Scholar20. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002;360:895-900. [PMID: 12354470] Google Scholar21. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184:92-9. [PMID: 21474646] Google Scholar22. Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan. A parallel, randomized trial. Ann Intern Med..2013;158:641-9. Google Scholar23. Archibald CJ, Auger WR, Fedullo PF, et al. Long-term outcome after pulmonary thromboendarterectomy. Am J Respir Crit Care Med. 1999;160:523-8. [PMID: 10430723] Google Scholar24. Madani MM, Auger WR, Pretorius V, et al. Pulmonary endarterectomy: recent changes in a single institution's experience of more than 2,700 patients. Ann Thorac Surg. 2012;94:97-103; discussion 103. [PMID: 22626752] Google Scholar25. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81. [PMID: 1603139] Google Scholar26. Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest. 1997;112:714-21. [PMID: 9315805] Google Scholar27. Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998;114:787-92. [PMID: 9743167] Google Scholar28. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122:164-72. [PMID: 20585012] Google Scholar29. Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012;141:354-62. [PMID: 21680644] Google Scholar30. Barst RJ, Rubin LJ, Long WA, et al; Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-301. [PMID: 8532025] Google Scholar31. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132:425-34. [PMID: 10733441] Google Scholar32. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999;99:1858-65. [PMID: 10199883] Google Scholar33. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology. 1999;30:641-8. [PMID: 10462369] Google Scholar34. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990;112:485-91. [PMID: 2107780] Google Scholar35. Gomberg-Maitland M, Tapson VF, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med. 2005;172:1586-9. [PMID: 16151039] Google Scholar36. Doran AK, Ivy DD, Barst RJ, Hill N, Murali S, Benza RL; Scientific Leadership Council of the Pulmonary Hypertension Association. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl. 2008:5-9. [PMID: 18638170] Google Scholar37. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257-63. [PMID: 16946127] Google Scholar38. Olschewski H, Simonneau G, Galiè N, et al; Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-9. [PMID: 12151469] Google Scholar39. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-9. [PMID: 8497283] Google Scholar40. Channick RN, Simonneau G, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119-23. [PMID: 11597664] Google Scholar41. Galiè N, Rubin Lj, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371:2093-100. [PMID: 18572079] Google Scholar42. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903. [PMID: 11907289] Google Scholar44. Galié N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46:529-35. [PMID: 16053970] Google Scholar45. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117:3010-9. [PMID: 18506008] Google Scholar46. Oudiz RJ, Galiè N, Olschewski H, et al; ARIES Study Group. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:1971-81. [PMID: 19909879] Google Scholar47. Rubin LJ, Badesch DB, Fleming TR, et al; SUPER-2 Study Group. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest. 2011;140:1274-83. [PMID: 21546436] Google Scholar48. Badesch DB, Hill NS, Burgess G, et al; SUPER Study Group. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007;34:2417-22. [PMID: 17985403] Google Scholar49. Simonneau G, Rubin LJ, Galiè N, et al; PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149:521-30. [PMID: 18936500] Google Scholar50. Galiè N, Ghofrani HA, Torbicki A, et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-57. [PMID: 16291984] Google Scholar51. Galiè N, Brundage BH, Ghofrani HA, et al; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119:2894-903. [PMID: 19470885] Google Scholar52. Barst RJ, Oudiz RJ, Beardsworth A, et al; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2011;30:632-43. [PMID: 21256048] Google Scholar53. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55:1915-22. [PMID: 20430262] Google Scholar54. Zhu B, Wang L, Sun L, Cao R. Combination therapy improves exercise capacity and reduces risk of clinical worsening in patients with pulmonary arterial hypertension: a meta-analysis. J Cardiovasc Pharmacol. 2012;60:342-6. [PMID: 22691882] Google Scholar55. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24:353-9. [PMID: 15358690] Google Scholar56. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2006;28:691-4. [PMID: 17012628] Google Scholar57. Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, S¿ndergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2010;31:1124-31. [PMID: 20202971] Google Scholar58. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006;114:1482-9. [PMID: 16982941] Google Scholar59. Grünig E, Ehlken N, Ghofrani A, et al. Effect of exercise and respiratory training on clinical progression and survival in patients with severe chronic pulmonary hypertension. Respiration. 2011;81:394-401. [PMID: 21311162] Google Scholar60. Cappola TP, Felker GM, Kao WH, Hare JM, Baughman KL, Kasper EK. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation. 2002;105:1663-8. [PMID: 11940544] Google Scholar61. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37:183-8. [PMID: 11153735] Google Scholar62. Hurdman J, Condliffe R, Elliot CA, et al. ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J. 2012;39:945-55. [PMID: 21885399] Google Scholar63. Badesch DB, Abman SH, Ahearn GS, et al; American College of Chest Physicians. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:35S-62S. [PMID: 15249494] Google Scholar64. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131:1917-28. [PMID: 17565025] Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySelected Disorders of the Cardiovascular SystemPrediction of pulmonary pressure after Glenn shunts by computed tomography–based machine learning modelsSelected Disorders of the Cardiovascular SystemHeart Rhythm Complexity Impairment in Patients with Pulmonary HypertensionDiagnosing and managing scleroderma-related pulmonary arterial hypertensionSelected Disorders of the Cardiovascular SystemAccuracy of CT Pulmonary Artery Diameter for Pulmonary Hypertension in End-Stage COPDCardiac Energy Metabolic Alterations in Pressure Overload–Induced Left and Right Heart Failure (2013 Grover Conference Series)Portopulmonary hypertension: An updateSelected Disorders of the Cardiovascular SystemPulmonary Venous HypertensionSeverity of Arterial and Chronic Thromboembolic Pulmonary Hypertension is Associated with Impairment of Heart Rate TurbulenceCT-Base Pulmonary Artery Measurementin the Detection of Pulmonary HypertensionA look at the upper heart chamber: the left atrium in chronic kidney diseasePharmacokinetic evaluation of treprostinil (oral) for the treatment of pulmonary arterial hypertensionPulmonary Venous Hypertension 7 May 2013Volume 158, Issue 9Page: ITC5-1KeywordsBrain natriuretic peptidesCardiovascular therapyCatheterizationHeartHeart diseasesHeart failureInterstitial lung diseasesLungsPulmonary diseasesPulmonary hypertension ePublished: 7 May 2013 Issue Published: 7 May 2013 Copyright & PermissionsCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...